. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Alzheimers Dement. 2012 Feb 1;8(3):180–187. doi: 10.1016/j.jalz.2011.02.011

Table 4.

Examination of an interaction between the dementia medication persistency index (PI) and sex as a predictor of progression on the MMSE and CDR-Sum.

PI	MMSE^*,^†			CDR-Sum^*,^†
PI	n	b (95% CI)	LR test	n	b (95% CI)	LR test
Any Dementia Medication	200			216
PI^* Male^* time		0.94 (−1.05, 2.94)	χ² =3.54, 2 df, p = 0.171		−0.49 (−2.16, 1.17)	χ² = 3.29, 2 df, p = 0.193
PI^* Male^* time ²		0.10 (−0.20, 0.39)			−0.11 (−0.36, 0.15)
Cholinesterase Inhibitor Only	175			191
PI^* Male^* time		1.02 (−2.08, 4.14)	χ² =9.26, 2 df, p = 0.010		0.71 (−2.02, 3.44)	χ² = 6.40, 2 df, p = 0.041
PI^* Male^* time ²		0.42 (−0.18, 1.03)			−0.52 (−1.06, 0.03)

Abbreviations: PI = Persistency Index; CI = confidence interval; MMSE=Mini-mental State Examination; CDR-Sum = Clinical Dementia Rating Scale - Sum of Boxscores

Using Mixed Effects Regression, all models adjusted for time, time², baseline age, sex, education, dementia duration at baseline, and any APOE E4 allele.

^†

A positive coefficient for MMSE represent a better performance whereas a negative coefficient for CDR-Sum represents a better performance.